Vitality Watch

Dossier pubmed review 01-oct-2026
Narrative review or expert overview without new data

Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.

Briefing card

Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.
Stage: review · pubmed · 01-oct-2026

Applies to developers of vascular senotherapeutics: this review argues systemic TLR4 inhibitors are unlikely to work and that endothelium-targeted delivery is the required next step.

Endothelial TLR4 acts as a context-dependent driver of vascular senescence and aging pathologies, so next-generation anti-aging therapy should use spatiotemporally targeted TLR4 inhibition (e.g., VCAM-1/E-selectin nanoparticles or engineered plant exosomes) rather than systemic pan-TLR4 blockade.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/acel.70757

build build 880 · 2bcef25 · 2026-11-18